CEL-SCI Corporation announced on July 11, 2025, that it reached an agreement with a leading Saudi Arabian pharmaceutical and healthcare company for a partnership. This collaboration will cover regulatory and commercial activities for Multikine in the Kingdom of Saudi Arabia.
A formal agreement is expected to be signed, with the Saudi partner filing a Breakthrough Medicine Designation application for Multikine with the Saudi Food and Drug Authority (SFDA) in the coming weeks. The SFDA's response time for such an application is approximately 60 days.
Following the granting of Breakthrough Medicine Designation, Multikine would immediately become available for patient access and reimbursement/sale in Saudi Arabia. This partnership aligns with Saudi Arabia’s Vision 2030 initiative to become a global biotech hub and addresses the expected doubling of head and neck cancer incidence in the MENA region by 2030.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.